Study to Improve Cancer Treatment Outcomes for Children, Teens, and Young Adults in Low- and Middle-Income Countries Focusing on Treatment Failures and Side Effects in Leukemia and Lymphoma

What this Trial Is About

This research aims to assess cancer treatment outcomes in children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries LMICs. It focuses especially on acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, which have poorer outcomes in these regions compared to high-income countries due to challenges like delayed diagnosis, limited access to therapies, and financial barriers. The study seeks to inform future efforts to improve care quality and reduce treatment failures through evidence-based strategies. The study involves a retrospective review of medical records from participating oncology centers in several LMICs, including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any cancer diagnosis, with particular attention to those diagnosed with ALL or LBL. Researchers will collect data on treatment failure incidence, therapy-related toxicities, and clinical outcomes over a three-year period following cancer diagnosis. No experimental treatments are administered the study uses existing medical records for analysis. Participants medical records will be reviewed to capture information on treatment failure, including relapse, progression, or abandonment, and therapy-related toxicities in the ALLLBL subgroup. Researchers will also analyze outcomes by cancer type, treatment regimen, age, and sociodemographic factors. The primary outcomes include incidence of treatment failure and toxicities within three years of diagnosis. This observational study will provide valuable data to guide improvements in cancer care for young patients in LMICs.

CAYA Cancer Retrospective Cohort Study